ALEMG Fundamental Analysis - LABORATOIRES EUROMEDIS

Fundamental Rating

Taking everything into account, ALEMG scores 3 out of 10 in our fundamental rating. ALEMG was compared to 65 industry peers in the Health Care Equipment & Supplies industry. While ALEMG seems to be doing ok healthwise, there are quite some concerns on its profitability. ALEMG is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALEMG had negative earnings in the past year.

The reported net income has been mixed in the past 5 years: ALEMG reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: ALEMG reported negative operating cash flow in multiple years.

1.2 Ratios

ALEMG's Return On Assets of 27.66% is amongst the best of the industry. ALEMG outperforms 98.46% of its industry peers.

Looking at the Return On Equity, with a value of 57.02%, ALEMG belongs to the top of the industry, outperforming 98.46% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	27.66%
ROE	57.02%
ROIC	N/A

ROA(3y)0.89%

ROA(5y)6.05%

ROE(3y)1.29%

ROE(5y)13.59%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALEMG has a better Profit Margin (24.05%) than 93.85% of its industry peers.

Looking at the Gross Margin, with a value of 31.89%, ALEMG is doing worse than 81.54% of the companies in the same industry.

In the last couple of years the Gross Margin of ALEMG has remained more or less at the same level.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	24.05%
GM	31.89%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.6%

GM growth 5Y1.2%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALEMG has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for ALEMG has been reduced compared to 5 years ago.

ALEMG has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.68, we must say that ALEMG is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of ALEMG (1.68) is worse than 64.62% of its industry peers.

ALEMG has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.41, ALEMG perfoms like the industry average, outperforming 52.31% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Altman-Z	1.68

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ALEMG has a Current Ratio of 3.47. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.

ALEMG has a better Current ratio (3.47) than 87.69% of its industry peers.

A Quick Ratio of 2.57 indicates that ALEMG has no problem at all paying its short term obligations.

ALEMG has a better Quick ratio (2.57) than 87.69% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.47
Quick Ratio	2.57

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALEMG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -178.48%.

Looking at the last year, ALEMG shows a very negative growth in Revenue. The Revenue has decreased by -38.33% in the last year.

The Revenue for ALEMG have been decreasing by -14.02% on average. This is quite bad

EPS 1Y (TTM)-178.48%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-142.68%

Revenue 1Y (TTM)-38.33%

Revenue growth 3Y-31.34%

Revenue growth 5Y-14.02%

Sales Q2Q%-47.27%

3.2 Future

Based on estimates for the next years, ALEMG will show a small growth in Earnings Per Share. The EPS will grow by 7.07% on average per year.

The Revenue is expected to decrease by -18.80% on average over the next years. This is quite bad

EPS Next Y8.35%

EPS Next 2Y7.07%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year7.54%

Revenue Next 2Y-18.8%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALEMG. In the last year negative earnings were reported.

Based on the Price/Forward Earnings ratio of 8.96, the valuation of ALEMG can be described as reasonable.

Based on the Price/Forward Earnings ratio, ALEMG is valued cheaper than 92.31% of the companies in the same industry.

ALEMG is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	8.96

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y7.07%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALEMG!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LABORATOIRES EUROMEDIS

EPA:ALEMG (11/28/2025, 7:00:00 PM)

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)10-27 2025-10-27

Earnings (Next)04-23 2026-04-23

Inst Owners1.67%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap11.48M

Revenue(TTM)36.22M

Net Income(TTM)12.58M

Analysts37.14

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	8.96
P/S	0.22
P/FCF	N/A
P/OCF	N/A
P/B	0.52
P/tB	0.52
EV/EBITDA	N/A

EPS(TTM)-2.15

EYN/A

EPS(NY)0.45

Fwd EY11.16%

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS18.22

BVpS7.69

TBVpS7.68

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	27.66%
ROE	57.02%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	24.05%
GM	31.89%
FCFM	N/A

ROA(3y)0.89%

ROA(5y)6.05%

ROE(3y)1.29%

ROE(5y)13.59%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.6%

GM growth 5Y1.2%

F-ScoreN/A

Asset Turnover1.15

Health

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.47
Quick Ratio	2.57
Altman-Z	1.68

F-ScoreN/A

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-178.48%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-142.68%

EPS Next Y8.35%

EPS Next 2Y7.07%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-38.33%

Revenue growth 3Y-31.34%

Revenue growth 5Y-14.02%

Sales Q2Q%-47.27%

Revenue Next Year7.54%

Revenue Next 2Y-18.8%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-86.02%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year73.57%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

LABORATOIRES EUROMEDIS / ALEMG.PA FAQ

What is the ChartMill fundamental rating of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALEMG.PA.

What is the valuation status for ALEMG stock?

ChartMill assigns a valuation rating of 3 / 10 to LABORATOIRES EUROMEDIS (ALEMG.PA). This can be considered as Overvalued.

What is the profitability of ALEMG stock?

LABORATOIRES EUROMEDIS (ALEMG.PA) has a profitability rating of 3 / 10.

What is the financial health of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

The financial health rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 5 / 10.

LABORATOIRES EUROMEDIS (ALEMG.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

LABORATOIRES EUROMEDIS / ALEMG.PA FAQ

What is the ChartMill fundamental rating of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

What is the valuation status for ALEMG stock?

What is the profitability of ALEMG stock?

What is the financial health of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?